Hemispherx files $150 million shelf registration covering stock, debt

By Devika Patel

Knoxville, Tenn., June 9 - Hemispherx Biopharma, Inc. filed a $150 million shelf registration in an S-3 filing with the Securities and Exchange Commission.

The registration covers common stock, preferred stock, warrants and debt securities.

The securities may be convertible.

Proceeds will be used to fund the commercialization of Alferon and Ampligen and for general corporate purposes.

Philadelphia-based Hemispherx develops drugs to treat debilitating disorders, like viral diseases and immune-system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.